INTRODUCTION {#s1}
============

Cardiovascular disease (CVD) is the leading cause of deaths worldwide with more than half from coronary heart disease (CHD) \[[@R1]\]. Although the mortality from heart disease has declined in recent years in the developed countries, the burden of CHD still remains alarmingly high, especially in the developing countries \[[@R1]-[@R3]\]. Various risk score systems have been developed to estimate the risk of cardiovascular events (including mortality) within a given time frame among the general population \[[@R4]-[@R7]\]. The most common score is from the Framingham Study \[[@R5]\] including age, categories of blood pressure (BP), cigarette use, total cholesterol or low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and diabetes. Although age, gender, hyperglycemia, dyslipidemia, hypertension and cigarette use are still important for CHD prognosis, convenient and efficient scoring assessments composed of these traditional factors for quantifying the long-term mortality risk among patients with CHD are limited.

Currently, few studies have developed scores or predictions for cardiovascular outcomes among CHD patients \[[@R8]-[@R10]\]. Most of these score assessments were developed among acute coronary syndrome (ACS) patients for short-term outcomes prediction, and were all performed in the developed countries. In addition, these scoring systems included many biomarkers, such as angiographic results, electrocardiographic changes or indicators of liver and renal dysfunction, some of which might not be detected for every patient. Practically, a risk stratification tool with routine clinical measurements which would be available for every patient might be simple and easy to understand and calculate by physicians as well as patients. Furthermore, since secondary prevention of CHD is targeted on the risk-reduction clinical treatment and self-management, knowing risk status by patients themselves would have an important impact on supporting and broadening the merits of treatments. The aim of the present study was to develop a simple predictive risk score using traditional factors to estimate the long-term risk of all-cause and cardiovascular mortality among patients with CHD.

RESULTS {#s2}
=======

General characteristics of the study population of the Guangdong Coronary Artery Disease Cohort (GCADC) study (as derivation cohort) at baseline were shown in Table [1](#T1){ref-type="table"}. We totally studied 1911 CHD patients in the GCADC study; the mean age was 63.6 years, and 65.1% were men. During the mean 4.9 years of follow-up, 232 deaths were identified, 159 of whom were due to cardiovascular causes. Compared with patients who survived during the follow-up, non-survivors were more likely to be older, had lower diastolic blood pressure (DBP) and higher fasting blood glucose (FBG), and had a high proportion of males, less education and less leisure-time physical activity. From the validation cohort of 1506 CHD patients using electronic medical records from the same hospitals, 83 deaths were reported during the mean follow-up period of 4.7 years, 46 of them were cardiovascular-related.

###### Baseline characteristics by mortality status among patients with coronary heart disease of the derivation cohort

  Characteristic                                  All patients   Survivors     Non-survivors   *P* for difference
  ----------------------------------------------- -------------- ------------- --------------- --------------------
  N                                               1911           1679          232             
  Gender (male, %)                                65.1           64.9          67.2            0.003
  Age at baseline (yrs)                           63.6           62.5 (0.26)   71.7 (0.71)     \<0.001
  Body mass index (kg/m^2^)                       23.9           23.9 (0.08)   23.6 (0.22)     0.26
  Systolic blood pressure (mm Hg)                 134            134 (0.56)    132 (1.54)      0.17
  Diastolic blood pressure (mm Hg)                76.5           76.8 (0.31)   74.8 (0.87)     0.036
  Fasting blood glucose (mmol/L)                  6.47           6.40 (0.07)   7.04 (0.18)     0.001
  High-density lipoprotein cholesterol (mmol/L)   41.9           1.09 (0.01)   1.05 (0.02)     0.08
  Low-density lipoprotein cholesterol (mmol/L)    115            2.96 (0.02)   3.03 (0.07)     0.30
  Triglycerides (mmol/L)                          1.85           1.86 (0.03)   1.72 (0.09)     0.14
  Total cholesterol (mmol/L)                      4.68           4.68 (0.03)   4.72 (0.07)     0.62
  Married (%)                                     90.8           92.2          81.4            0.005
  Years of education (%)                                                                       0.005
   ≤9                                             59.6           58.6          67.5            
   10-12                                          22.1           21.9          23.3            
   ≥13                                            18.4           19.5          9.2             
  Smoking (%)                                                                                  0.67
   Never                                          60.4           59.7          65.5            
   Past                                           8.8            8.5           11.6            
   Current                                        30.7           31.8          22.8            
  Alcohol drinking (%)                                                                         0.71
   Never                                          78.3           77.9          81.2            
   Past                                           6.7            6.7           6.6             
   Current                                        15.1           15.5          12.2            
  Leisure-time physical activity (%)                                                           \<0.001
   None                                           33.5           31.9          50.0            
   ≤30 minutes/day                                21.6           21.3          24.6            
   \>30 minutes/day                               44.9           46.8          25.4            
  Type of coronary heart disease (%)                                                           0.60
   Acute coronary syndrome                        59.8           59.8          59.5            
   Chronic coronary heart disease                 40.2           40.2          40.5            
  Family history of coronary heart disease (%)    8.7            9.0           6.5             0.68
  Use of medication before admission (%)                                                       
   Antihypertensive drugs                         48.9           47.9          55.7            0.88
   Anti-diabetic drugs                            16.5           15.7          22.2            0.10
   Lipid-lowering drugs                           12.1           12.3          10.9            0.60
   Anti-platelet drugs                            19.7           18.8          25.7            0.13

Abbreviations: Data are mean (standard error) or percentage; all variables are adjusted for age and gender, except for age (adjusted for gender only) and gender (adjusted for age only).

The associations of different levels of selected risk factors at baseline with the risks of all-cause and cardiovascular mortality were shown in Table [2](#T2){ref-type="table"}. After multivariate adjustment (alcohol consumption, marriage, family history of CHD, types of CHD, leisure-time physical activity, and BMI), gender, age, FBG, and HDL-C were significantly predictive for all-cause and cardiovascular mortality over 4-year and whole follow-up periods, whereas LDL-C was only predictive for cardiovascular mortality in the whole follow-up period. BP and smoking were not associated with an increased risk of mortality in either 4-year or whole period of follow-up. Systolic blood pressure (SBP) was positively correlated with LDL-C and HDL-C, and DBP was positively correlated with LDL-C and negatively correlated with FBG (all r\<0.1, *P*\<0.05) (data no shown). Risk scores were given for different sexes, different levels of age, FBG, HDL-C and LDL-C (Table [3](#T3){ref-type="table"}). BP and smoking have not been included in the final risk scores because they were not significant predictors in all multivariate models.

###### Hazard ratios for all-cause and cardiovascular mortality according to major risk factors among patients with coronary heart disease of the derivation cohort

  Variable                        No. of CHD patients   4-year follow-up   Whole period of follow-up                                                                        
  ------------------------------- --------------------- ------------------ --------------------------- ------------------ ------------------ ----- ----- ------------------ ------------------
  Gender                                                                                                                                                                    
   Female                         666                   53                 34                          1.00               1.00               76    46    1.00               1.00
   Male                           1245                  127                95                          1.92 (1.33-2.77)   2.32 (1.49-3.62)   156   113   1.58 (1.15-2.17)   1.95 (1.31-2.89)
  Age, years                                                                                                                                                                
   \<60                           682                   18                 12                          1.00               1.00               25    16    1.00               1.00
   60-69                          569                   41                 35                          3.52 (2.00-6.18)   4.74 (2.43-9.26)   56    44    3.33 (2.06-5.39)   4.33 (2.41-7.77)
   ≥70                            660                   121                82                          8.20 (4.89-13.7)   8.48 (4.50-16.0)   151   99    7.28 (4.67-11.3)   7.63 (4.38-13.3)
   *P* for difference                                                                                  \<0.001            \<0.001                        \<0.001            \<0.001
  Fasting blood glucose, mmol/L                                                                                                                                             
   \<5.6                          796                   52                 31                          1.00               1.00               67    37    1.00               1.00
   5.6-6.9                        381                   41                 29                          1.55 (1.02-2.35)   1.86 (1.11-3.11)   51    33    1.64 (1.13-2.38)   1.89 (1.17-3.04)
   ≥7.0 or known diabetes         734                   87                 69                          1.75 (1.23-2.48)   2.31 (1.50-3.57)   114   89    1.87 (1.37-2.55)   2.59 (1.75-3.84)
   *P* for difference                                                                                  0.007              0.001                          \<0.001            \<0.001
  HDL cholesterol, mmol/L                                                                                                                                                   
   \<1.03                         896                   101                77                          1.63 (1.17-2.28)   1.94 (1.29-2.92)   125   93    1.53 (1.15-2.05)   1.93 (1.35-2.78)
   1.03-1.54                      901                   64                 40                          1.00               1.00               89    52    1.00               1.00
   ≥1.55                          114                   15                 12                          2.11 (1.18-3.75)   2.92 (1.50-5.68)   18    14    1.67 (0.99-2.80)   2.42 (1.32-4.44)
   *P* for difference                                                                                  0.003              0.001                          0.008              \<0.001
  LDL cholesterol, mmol/L                                                                                                                                                   
   \<2.59                         709                   76                 51                          1.00               1.00               93    59    1.00               1.00
   2.59-4.14                      981                   83                 60                          0.95 (0.69-1.30)   1.02 (0.70-1.50)   108   75    0.99 (0.75-1.31)   1.10 (0.78-1.56)
   ≥4.15                          221                   21                 18                          1.29 (0.78-2.12)   1.78 (1.01-3.13)   31    25    1.54 (1.01-2.36)   2.14 (1.31-3.50)
   *P* for difference                                                                                  0.48               0.10                           0.086              0.007
  Blood pressure, mm Hg                                                                                                                                                     
   \<120/80                       443                   38                 28                          1.00               1.00               50    34    1.00               1.00
   ≥120-139/80-89                 717                   61                 42                          1.04 (0.69-1.57)   1.01 (0.62-1.65)   81    54    1.01 (0.70-1.45)   1.06 (0.68-1.64)
   ≥140/90                        751                   81                 59                          1.05 (0.70-1.57)   1.06 (0.66-1.69)   101   71    0.95 (0.67-1.36)   1.03 (0.67-1.58)
   *P* for difference                                                                                  0.97               0.97                           0.92               0.97
  Smoking status                                                                                                                                                            
   Never                          1155                  117                83                          1.00               1.00               152   102   1.00               1.00
   Past                           169                   18                 14                          0.84 (0.50-1.42)   0.87 (0.48-1.58)   27    18    1.01 (0.65-1.57)   0.92 (0.54-1.57)
   Current                        587                   45                 32                          0.80 (0.54-1.18)   0.73 (0.46-1.17)   53    39    0.76 (0.53-1.09)   0.74 (0.49-1.13)
   *P* for difference                                                                                  0.49               0.42                           0.28               0.37

Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Adjusted for alcohol consumption, marriage, family history of coronary heart disease, type of coronary heart disease, leisure-time physical activity, and body mass index.

###### Risk score coefficients for all-cause mortality and cardiovascular mortality over 4 years and whole follow-up

  Year of follow-up               4-year of follow-up   Whole period of follow-up        
  ------------------------------- --------------------- --------------------------- ---- ----
  Gender                                                                                 
   Female                         0                     0                           0    0
   Male                           7                     8                           5    7
  Age, years                                                                             
   \<60                           0                     0                           0    0
   60-69                          13                    16                          12   15
   ≥70                            21                    21                          20   20
  Fasting blood glucose, mmol/L                                                          
   \<5.6                          0                     0                           0    0
   5.6-6.9                        4                     6                           5    6
   ≥7.0 or known diabetes         6                     8                           6    10
  HDL cholesterol, mmol/L                                                                
   \<1.03                         5                     7                           4    7
   1.03-1.54                      0                     0                           0    0
   ≥1.55                          7                     11                          5    9
  LDL cholesterol, mmol/L                                                                
   \<2.59                         0                     0                           0    0
   2.59-4.14                      0                     0                           0    1
   ≥4.15                          3                     6                           4    8

Abbreviations: CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

When we stratified risk scores into quartiles, the risk scores during both 4-year and the whole period of follow-up showed a graded increased association with the risks of all-cause and cardiovascular mortality (all *P*\>0.001) (Table [4](#T4){ref-type="table"}). Compared with patients in the lowest risk group (quartile 1 of risk score), the multivariable-adjusted hazard ratios (HRs) for all-cause and cardiovascular mortality among patients with the highest risk (quartile 4 of risk score) were 10.6 \[95% confidence interval (CI): 5.66-20.0\] and 15.1 (95% CI: 6.53-35.0) over 4-year follow-up; 8.86 (95% CI: 5.15-15.3) and 14.5 (95% CI: 6.68-31.6) over the whole follow-up, respectively. Each 1 value increase in risk score contributed to appropriately 10% increased risk of all-cause mortality (HR 1.10, 95% CI: 1.08-1.13 for 4-year follow-up and HR 1.11, 95% CI: 1.09-1.13 for whole period of follow-up) and cardiovascular mortality (HR 1.11, 95% CI: 1.08-1.13 for 4-year follow-up and HR 1.10, 95% CI: 1.08-1.12 for whole period of follow-up). The discrimination for risk scores was shown in Table [5](#T5){ref-type="table"}. Assessed by the area under the receiver operating characteristic curve (AUROC), these four risk score models for risks of all-cause and cardiovascular mortality over 4-year and whole period of follow-up demonstrated the discriminatory capacity from 0.744 to 0.763 (all *P*\<0.001) for the derivation cohort and 0.736 to 0.756 (all *P*\<0.001) for the validation cohort, respectively.

###### Hazard ratios for all-cause and cardiovascular mortality according to risk score quartiles among patients with coronary heart disease of the derivation cohort over 4 years and the whole follow-up

  Model                                                                  Quartiles of risk score   *P* for trend      Each 1 score increase                                
  ---------------------------------------------------------------------- ------------------------- ------------------ ----------------------- ------------------ --------- ------------------
  4-year of follow-up                                                                                                                                                      
   All-cause mortality                                                                                                                                                     
   Range of scores                                                       0-13                      14-21              22-29                   30-42                        
   No. of CHD patients                                                   510                       443                482                     476                          
   No. of deaths                                                         11                        14                 57                      98                           
   Multiple adjusted hazard ratios[^a^](#tfn_002){ref-type="table-fn"}   1.00                      1.51 (0.69-3.34)   6.18 (3.23-11.8)        10.6 (5.66-20.0)   \<0.001   1.10 (1.08-1.13)
   Cardiovascular mortality                                                                                                                                                
   Range of scores                                                       0-16                      17-27              28-35                   36-50                        
   No. of CHD patients                                                   503                       471                475                     462                          
   No. of deaths                                                         6                         9                  42                      72                           
   Multiple adjusted hazard ratios[^a^](#tfn_002){ref-type="table-fn"}   1.00                      1.63 (0.58-4.58)   7.94 (3.36-18.8)        15.1(6.53-35.0)    \<0.001   1.11 (1.08-1.13)
  Whole period of follow-up                                                                                                                                                
   All-cause mortality                                                                                                                                                     
   Range of scores                                                       0-11                      12-20              21-26                   27-39                        
   No. of CHD patients                                                   465                       484                469                     493                          
   No. of deaths                                                         15                        24                 71                      122                          
   Multiple adjusted hazard ratios[^a^](#tfn_002){ref-type="table-fn"}   1.00                      1.64 (0.86-3.14)   5.44 (3.11-9.53)        8.86 (5.15-15.3)   \<0.001   1.11 (1.09-1.13)
   Cardiovascular mortality                                                                                                                                                
   Range of scores                                                       0-17                      18-26              27-34                   35-52                        
   No. of CHD patients                                                   448                       484                509                     470                          
   No. of deaths                                                         7                         12                 51                      89                           
   Multiple adjusted hazard ratios[^a^](#tfn_002){ref-type="table-fn"}   1.00                      1.71 (0.67-4.35)   7.25 (3.28-16.0)        14.5 (6.68-31.6)   \<0.001   1.10 (1.08-1.12)

Abbreviations: CHD, coronary heart disease.

Adjusted for smoking, alcohol consumption, marriage, family history of coronary heart disease, types of coronary heart disease, leisure-time physical activity, blood pressure categories, and body mass index.

###### Discrimination measured by AUROC for risk score over 4 years and whole period of follow-up

  Model                                      AUROC               *P* value
  ------------------------------------------ ------------------- -----------
  Derivation cohort                                              
  4-year of follow-up                                            
   Risk score for all-cause mortality        0.754 (0.72-0.79)   \<0.001
   Risk score for cardiovascular mortality   0.763 (0.72-0.80)   \<0.001
  Whole period of follow-up                                      
   Risk score for all-cause mortality        0.744 (0.71-0.78)   \<0.001
   Risk score for cardiovascular mortality   0.762 (0.73-0.80)   \<0.001
  Validation cohort                                              
  4-year of follow-up                                            
   Risk score for all-cause mortality        0.756 (0.70-0.82)   \<0.001
   Risk score for cardiovascular mortality   0.736 (0.67-0.80)   \<0.001
  Whole period of follow-up                                      
   Risk score for all-cause mortality        0.736 (0.68-0.79)   \<0.001
   Risk score for cardiovascular mortality   0.743 (0.69-0.80)   \<0.001

Abbreviations: AUROC, area under receiver operating characteristic curve.

DISCUSSION {#s3}
==========

We developed a simple risk score system (including sex, age, FBG, HDL-C, and LDL-C) for estimating prognosis of all-cause and CVD mortality among Chinese patients with CHD over a 4-year and a whole period of follow-up.

In the present study, we observed that men with CHD were at higher risk of mortality than women with CHD, which was the same as previous studies \[[@R4], [@R8]\]. As expected, age was always found to be the strongest predictor of the risk of mortality among patients with CHD. For other traditional factors studied, both impaired fasting glucose (FBG: 5.6-6.9 mmol/L) and diabetes were significantly associated with increased risks of mortality among CHD patients. We also found that the hazard ratios of mortality associated with FBG increased slightly with the increased length of follow-up, which indicated that FBG levels might have a significant long-term impact on CHD prognosis. The U-shape association of HDL-C with the risk of mortality was consistent with other studies \[[@R11], [@R12]\]. Under particular conditions, HDL would lose its protective functions (antioxidant, anti-inflammation, anti-apoptotic, ameliorate endothelial dysfunction) and gain dysfunction, which might contribute to inflammatory processes that promote atherosclerosis in CHD patients \[[@R13]\]. It suggests that controlling HDL-C at a reasonable range is necessary. Since LDL-C and HDL-C would be always detected as a pair of lipoprotein fractions in routine clinical examinations, we selected LDL-C, which was positively associated with the risk of mortality among CHD patients, instead of total cholesterol in the present study. High BP and cigarette use have been thought to be strong predictors for mortality among the general population. However, in the present study, we did not find any association of BP and cigarette use with the risk of mortality among patients with CHD. The lack of significant association between BP and risk of mortality might be due to high prevalence of using anti-hypertensive medication (48.9%) among patients with CHD. As recommended by the guidelines \[[@R14]\], the tobacco user would be asked to quit smoking and pay more attention to secondary prevention, which partially explained the non-significant results. Taking multiple risk factors into account simultaneously might optimize the ability to estimate the prognosis of CHD patients. To the best of our knowledge, this is the first study that developed risk score assessments in Chinese patients with CHD.

Several previous studies have developed risk prediction scores for CVD risk among CHD patients with an acute setting \[[@R9]\]. TIMI risk score \[[@R15]\] provides a convenient bedside risk score for predicting 30-day mortality in patients with ST-elevation myocardial infarction while PURSUIT risk score \[[@R16]\] predicts 30-day outcomes for patients with ACS but without persistent ST-segment elevation. Granger *et al*. used 11,389 ACS patients enrolled in the Global Registry of Acute Coronary Events (GRACE) to develop the GRACE risk score for predicting mortality, but the median time of death was 4 days after hospital presentation \[[@R17]\]. Although these scoring assessments have been demonstrated significant discriminatory ability for mortality \[[@R9]\], they could not avoid the potential bias caused by premature death or the presence of occult diseases at baseline with the very short-term follow-up, and could not extend to all CHD outpatients.

Marschner et al. \[[@R8]\] developed a long-term risk stratification with 8557 CHD patients in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) study in Australia and New Zealand with an acute cardiac event 3-36 months before inclusion, which had been proposed as one of the first risk assessment scores for both ACS and stable CHD patients. As a strong predictor for prognosis of CHD in our study, LDL-C was not included in LIPID score because of missing data \[[@R8]\]. HDL-C and diabetes status were only divided into two classes in the LIPID risk score. Battes et al. \[[@R18]\] recently developed a cardiovascular risk assessment model in patients with established coronary artery disease, consisting of 12,218 patients in EUROPA database, which also used diabetes status instead of glucose concentrations. In contrast to their results, we found that non-diabetic glucose concentrations (impaired fasting glucose, FBG: 5.6-6.9 mmol/L) and higher HDL-C levels (≥1.55 mmol/L) were associated with an increased risk of mortality, indicating that including FBG and HDL-C as dichotomization variables might be simple to calculate, but it would result in inaccuracy for risk stratification by missing important information.

Another kind of risk scores has been developed in the CHD population for predicting long-term cardiovascular outcomes to stratify CHD patients before therapy like percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) surgery \[[@R19]-[@R21]\]. Thus, some complicated variables like severity of illness (number of diseased vessels, ejection fraction, and hemodynamic state, et al.) and the presence of several comorbidities and prior history (cerebrovascular disease, peripheral arterial disease, congestive heart failure, malignant ventricular arrhythmia, chronic obstructive pulmonary disease, diabetes mellitus, and renal failure et al.) would be included in the risk stratification. Complicated procedures might result in seldom use in the clinic. Unlike these previous risk scores for CHD patients, our risk scores only integrated available traditional measurements which could be detected for every patient routinely and easy to use. Of course, incorporating more clinical results or novel biomarkers would increase the predictive discrimination \[[@R22]\]. But it does not meet our original objective for building a simple and economical assessment; and additional costs for the measurements of unconventional biomarkers might limit the use of risk scores in clinical practice, especially in the developing countries. More importantly, our present risk scores, validated in the external cohort (AUROCs from 0.736-0.756, all *P*\<0.001), could also offer strong discriminatory capacity when assessing with AUROC.

There are several limitations in the present study. First, we enrolled participants from hospitals where in-patients may have a more severe disease status, bias may occur. But we recruited both acute and chronic CHD patients, and some of them were electively admitted patients with mild status in order to reduce the bias. Second, although our analyses adjusted for an extensive set of CVD confounding factors, residual confounding due to the measurement error in the assessment of confounding factors or unmeasured factors for all CHD patients cannot be excluded. Third, we only measured the risk factors at baseline and did not further measure them during follow-up. Thus, more studies are warranted to confirm our risk assessments.

In conclusion, we have developed predictive risk scores for all-cause and cardiovascular mortality for patients with CHD. These simple risk scores are based on routinely available clinical information and could be easily calculated. These simple risk scores might be useful, in addition to CHD treatments and the shared decision-making tools between physicians and patients for a more intensive secondary prevention treatment.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

GCADC study was conducted as a derivation cohort. Details of the GCADC study about aims, selection, criteria and ascertainment of CHD have been published previously \[[@R23], [@R24]\]. Participants who were admitted to the Cardiology Department of three superior specialty hospitals in Guangdong (Guangzhou Military General Hospital, Sun Yat-Sen Memorial Hospital, and First Affiliated Hospital of Sun Yat-Sen University) and diagnosed as coronary artery disease \[International Classification of Diseases (ICD)-10 codes I20-I25\] according to World Health Organization 1999/2000 guidelines \[[@R25], [@R26]\] between October 2008 and December 2011were recruited \[[@R23]\]. Briefly, we included 1911 CHD patients of 40 to 85 years old after excluding participants with incomplete data at baseline (n=69). Patients with ACS were defined as the occurrence of any of unstable angina pectoris, ST-segment elevation myocardial infarction, and non-ST-segment elevation myocardial infarction within 3 months. Using the same inclusion and exclusion criteria and diagnosis of CHD as the GCADC study, we additionally recruited 1615 CHD patients via electronic medical records. After excluding 109 patients with incomplete data, we finally enrolled 1506 participants as the external validation cohort. Written informed consent was obtained from each patient of GCADC study; we did not obtain informed consent from participants in the validation cohort because we used anonymized data compiled from electronic medical records. The study plan for the GCADC study and the whole analysis plan were conducted according to the principles expressed in the Declaration of Helsinki and approved by the Sun Yat-Sen University Ethics Committee.

Measurements {#s4_2}
------------

In the GCADC study, each patient\'s general information of examination date, birth date, gender, address, education level, marriage, leisure-time physical activity, smoking habits, alcohol consumption, dietary intake, family history of diseases, and use of medication before admission was ascertained by a standardized questionnaire and a validated food frequency questionnaire \[[@R27]\] through a face-to-face interview. We classified smoking habits and alcohol consumption into three groups: never, past, or current. Current smoking was defined as regularly at least one cigarette per day and lasting for more than 6 months before the study, and current alcohol drinking was defined as drinking any type of alcoholic beverages at least once a week and lasting for half a year before the study. Family history of CHD was self-reported, including CHD history for all first-degree relatives.

Clinical characteristics of patients from the derivation and validation cohorts were extracted from the electronic record system. At admission, height and weight were measured by trained nurses. Body mass index (BMI) was defined as the weight in kilograms divided by the square of height in meters. Two BP determinations were made after the patients had been sitting at least 5 minutes, and the average was used for the analyses. Blood was drawn at the baseline examination after an overnight fasting. Lipids and FBG were determined by standardized methods using the Hitachi automatic analyzer 7600-020 (Hitachi, Tokyo, Japan).

Prospective follow-up {#s4_3}
---------------------

Annual follow-up information was obtained from hospital medical records of readmission, telephone contacts with patients or their immediate family members, and death registration at the Guangdong Provincial Center for Disease Control and Prevention. The current surveys were followed to the end of June 2015 or patient\'s death if the date was prior to June 2015. We used the ICD codes to code the cause of death; the ICD codes I00--I99 were classified as CVD deaths.

Statistical analyses {#s4_4}
--------------------

Differences in baseline characteristics from the derivation cohort according to death status were tested by the general linear model for continuous variables and logistic regression for categorical variables after adjusting age and gender (except for age and gender). Major traditional risk factors (age, FBG, HDL-C, LDL-C, BP, and cigarette use) have been grouped into three classes: (1) age, \<60, 60-69, ≥70 years; (2) FBG, \<5.6, 5.6-6.9, ≥7.0 mmol/L and known diabetes (diabetes diagnosed before the baseline examinations); (3) HDL-C, \<1.03, 1.03-1.54, ≥1.55 mmol/L; (4) LDL-C, \<2.59, 2.59-4.14, ≥4.15 mmol/L; (5) BP, \<120/80, 120-139/80-89, ≥140/90 mm Hg; (6) smoking status, never, past, current. Cox proportional hazards models were performed to determine the associations between baseline major risk factors (gender, age, FBG, HDL-C, LDL-C, BP, and cigarette use) and the risk of all-cause and CVD mortality in both 4-year and whole follow-up periods, respectively. All analyses were adjusted for alcohol drinking, marriage, leisure-time physical activity, family history of CHD, type of CHD, and BMI. The selected risk factors were included as categories in the risk score systems to allow for possible non-linear effects of the factors and so that a risk score can be evaluated for a given individual by simply summing scores corresponding with the categories for each factor. We gave a risk score for each category of each factor, except for BP and smoking status because BP and smoking were not significant predictors in all multivariable-adjusted Cox models. These scores were beta coefficients, formed with the Cox model, multiplied by 10 and rounded to the closest integer \[[@R4]\]. The risk score for an individual was obtained by summing the scores for the appropriate level of each of the risk factors. The associations of risk scores for all-cause and cardiovascular mortality over 4-year and whole period of follow-up were estimated by Cox models after adjusting for smoking, alcohol drinking, marriage, leisure-time physical activity, family history of CHD, types of CHD, BP categories, and BMI. Risk scores were included in the Cox model in two ways: as quartiles and as continuous variables. We additionally conducted the Pearson correlation coefficients to assess the correlation between BP and other traditional factors.

The discrimination of capacity of different risk score groups for the derivation cohort and the validation cohort was assessed by the AUROC. Statistical significance was considered to be *P*\<0.05. All statistical analyses were performed using PASW for Windows, version 20.0 (IBM SPSS Inc., Chicago, IL).
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